← Back to Search

Diagnostic Test

Liquid Biopsy for Lung Cancer

N/A
Waitlist Available
Led By Nathan Pennell, MD, PhD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up an average of 30 days
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if using blood tests can help start treatment sooner for patients with newly diagnosed lung cancer. The goal is to reduce the time it takes to begin treatment.

Who is the study for?
This trial is for new patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who plan to receive systemic therapy and are referred to the Cleveland Clinic Taussig Cancer Center without prior genetic testing results. It's not open to those who've had previous treatment or adequate molecular testing for their current NSCLC diagnosis.
What is being tested?
The study is examining whether liquid biopsies can speed up the start of treatment in advanced NSCLC patients. A liquid biopsy involves taking a blood sample to search for cancer cells, which may help in quicker decision-making regarding therapy.
What are the potential side effects?
Since this trial focuses on diagnostic procedures rather than treatments, side effects are minimal and primarily related to blood draw complications like bruising, pain at the puncture site, or fainting.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~an average of 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and an average of 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
TTT measured in days
Secondary study objectives
Rate of actionable biomarker discovery
Rate of appropriate guideline-directed therapy based upon testing results
Time to actionable genetic testing results

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Liquid biopsyExperimental Treatment1 Intervention
A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liquid biopsy
2017
N/A
~210

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
465 Previous Clinical Trials
32,485 Total Patients Enrolled
Nathan Pennell, MD, PhDPrincipal InvestigatorCleveland Clinic, Case Comprehensive Cancer Center
3 Previous Clinical Trials
35 Total Patients Enrolled

Media Library

Liquid biopsy (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04474613 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Liquid biopsy
Non-Small Cell Lung Cancer Clinical Trial 2023: Liquid biopsy Highlights & Side Effects. Trial Name: NCT04474613 — N/A
Liquid biopsy (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04474613 — N/A
~4 spots leftby Dec 2024